Supporting 0 to 1 (Idea to NewCo)

Biotech Startups

 

Viva Ventures Biotech Fund

 

We are a corporate VC fund that focuses on investments in global first-in-class, discovery-stage biotech startups with significant growth potential. Viva Ventures is one of very few biotech VCs that have extensive expertise and industry know-how for early stage investments.

Supporting Biotech Startups since 2008

Viva Ventures Biotech Fund is backed by the founders of top biotech startups and chief scientists of incubator centers, giving us access to the top startups around the world including Viva Biotech incubators, Boston CIC, and Hong Kong Science Park. Viva Ventures Fund I is purely financed by Dr. Jun Mao.

Our Strategies

 

Our Investment Thesis:

Early Stage = Achieve Superior Return

Investment Stage.png
Investment Stage2.png

How to Achieve Higher Success Rate:

Genetic Linkage, Biomarkers and SBDD

Phase 2a/2 Clinical Success Rates

Higher Success Rate.png

Impact of Structure-Based Drug Design (SBDD)

Probality of High Affinity.png

*Source: Nature Review, Volume 13, June 2014

  • Projects that showed greater confidence in target validation through human genetic target linkage to the disease were less likely to fail owing to a lack of efficacy

  • 73% of projects with some genetic linkage of the target to the disease were active or successful in Phase II compared with 43% of projects without such data, also that of projects with biomarkers could exceed 80%

Deal Flow Funnel

Deal flow.png

Global Ecosystem for Deal Sourcing and Exiting

ecosystem-blue.png

Global Pharmas and Biotech Companies Include:

MNC pharms.png
Biotechs.png
TopResearchInstitute.png

Our Portfolio Overview

 

Diversified Portfolio

Portfolio Donut Chart.jpg

* Including all the projects invested by Fund I, Fund II and Fund III

Drug Description.PNG

Our Team

 

Fund Management

Jun Mao-低分辨率.jpg

Jun Mao, PhD (UK)

Founder and Chairwoman

 

  • Founding Director of Viva Biotech, a HK listed company with 100X+ investment return

  • Active biotech investor since 2008, invested 13 biotech and drug discovery startups

  • Working at top tier IB in City of London 1996-2009 after Ph.D. in Theoretical Physics (UK)

Logos for mao2.png
Lou Tartaglia PhD.png

Lou Tartaglia, PhD (US)

Partner

  • Former Partner at Third Rock Ventures, CEO of Solstice Biologics, General Manager at GeneLogic, and Vice President of Metabolic Diseases at Millennium Pharmaceuticals 

Logos for partners1.png
JMCR_LOGO_4_edited.jpg

About 30 Top GP Advisory Partners

  • 20+ years top biotech VC and/or drug discovery businesses   

GP Advisor logos.png

Our partners have extensive experience & track record:

GP Advisory Partners’ Role

  • Deal Sourcing

  • Deal Evaluation

  • DD & Negotiation

  • Exit Support

GP Advisory Partners’ Profile

  • Inventors of listed/ clinical stage drugs

  • 20+ years of experience in drug discovery

  • Diversified expertise

  • Carry sharing

  • None compete

  • Right of first to know

Scientists.png

Contact Us

 

Send us a business plan

If you have a great early-stage biotechnological or pharmaceutical  project align with our investment strategy, please send your business plan to info@vivaventuresbiotech.com. We look forward to it!

Send us a message

arrow&v

Thanks for the message!